 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| AAA603 / Novartis
Enrollment change, Trial completion date, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Apr 25, 2024
P1/2, N=51, Recruiting, Sponsor: Advanced Accelerator Applications
N=86 --> 51 | Trial completion date: Oct 2025 --> Dec 2026
- AAA603 / Novartis
Trial in progress: Evaluation of the safety, tolerability, whole-body distribution, radiation dosimetry and antitumor activity of 177Lu-NeoB in patients with advanced solid tumors expressing gastrin-releasing peptide receptor (GRPR) (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_7921;
N=86 --> 51 | Trial completion date: Oct 2025 --> Dec 2026 Abstract is embargoed at this time.
- | AAA603 / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (clinicaltrials.gov) - Dec 6, 2023
P1, N=45, Recruiting, Sponsor: Novartis Pharmaceuticals
Abstract is embargoed at this time. Trial completion date: Dec 2030 --> Oct 2029 | Trial primary completion date: Jun 2027 --> Oct 2029
- | AAA603 / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (clinicaltrials.gov) - Oct 5, 2023
P1, N=45, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2030 --> Oct 2029 | Trial primary completion date: Jun 2027 --> Oct 2029 Trial primary completion date: Nov 2024 --> Jun 2027
- || AAA603 / Novartis, Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (clinicaltrials.gov) - Oct 4, 2023
P1, N=45, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2024 --> Jun 2027 Not yet recruiting --> Recruiting
- || AAA603 / Novartis
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma (clinicaltrials.gov) - Jul 5, 2023
P1, N=48, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Jan 2025 --> Dec 2025 | Initiation date: Aug 2023 --> Apr 2024 | Trial primary completion date: Dec 2024 --> Oct 2025
- || AAA603 / Novartis, Kisqali (ribociclib) / Novartis
New P1 trial, Combination therapy, Metastases: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (clinicaltrials.gov) - May 23, 2023
P1, N=45, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || AAA603 / Novartis
Trial completion date, Trial primary completion date, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Apr 26, 2023
P1/2, N=86, Recruiting, Sponsor: Advanced Accelerator Applications
Trial completion date: Jan 2025 --> Dec 2025 | Initiation date: Aug 2023 --> Apr 2024 | Trial primary completion date: Dec 2024 --> Oct 2025 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Sep 2025
- || AAA603 / Novartis
New P1 trial, Combination therapy: Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma (clinicaltrials.gov) - Feb 22, 2023
P1, N=42, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || AAA603 / Novartis
Trial completion date, Trial primary completion date, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Aug 31, 2021
P1/2, N=86, Recruiting, Sponsor: Advanced Accelerator Applications
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Sep 2025 Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Aug 2023
- ||| AAA603 / Novartis
Enrollment open, Trial completion date, Trial primary completion date, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Aug 9, 2020
P1/2, N=71, Recruiting, Sponsor: Advanced Accelerator Applications
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Aug 2023 Suspended --> Recruiting | Trial completion date: Sep 2022 --> Apr 2024 | Trial primary completion date: Sep 2022 --> Apr 2024
- ||||| AAA603 / Novartis
Trial suspension, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Apr 14, 2020
P1/2, N=71, Suspended, Sponsor: Advanced Accelerator Applications
Suspended --> Recruiting | Trial completion date: Sep 2022 --> Apr 2024 | Trial primary completion date: Sep 2022 --> Apr 2024 Recruiting --> Suspended
- | AAA603 / Novartis
Enrollment open, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Jul 24, 2019
P1/2, N=71, Recruiting, Sponsor: Advanced Accelerator Applications
Recruiting --> Suspended Not yet recruiting --> Recruiting
- || AAA603 / Novartis
Trial initiation date, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Jun 3, 2019
P1/2, N=71, Not yet recruiting, Sponsor: Advanced Accelerator Applications
Not yet recruiting --> Recruiting Initiation date: Mar 2019 --> Jun 2019
- |||| AAA603 / Novartis
New P1/2 trial, Metastases: NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (clinicaltrials.gov) - Mar 13, 2019
P1/2, N=71, Not yet recruiting, Sponsor: Advanced Accelerator Applications